Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 8

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

453

HTML

2911

Figures (1-5)

123

Tables (1-1)

121

Sum=3608

Apr 15, 2004 (publication date) through Apr 24, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Liver Cancer

World J Gastroenterol. Apr 15, 2004; 10(8): 1146-1151
Published online Apr 15, 2004. doi: 10.3748/wjg.v10.i8.1146

Full Size Figure Download Figure

Figure 3 Percentages of lymphocyte subsets in peripheral blood of HCC patients before and after CIK cell therapy.

Citation: Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF, Feng YY, Fan ZP, Xu DP, Wang FS. Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004; 10(8): 1146-1151
URL: https://www.wjgnet.com/1007-9327/full/v10/i8/1146.htm
DOI: https://dx.doi.org/10.3748/wjg.v10.i8.1146